OncLive® On Air

Breast Cancer Briefing, hosted by Sara Nunnery, MD, MSCI, a breast medical oncologist and the director of Breast Cancer Research at Tennessee Oncology in Nashville, is a podcast series that breaks down the latest news in breast cancer research, one conversation at a time.
In this episode, Dr Nunnery sat down with MinhTri Nguyen, MD, a breast medical oncologist, assistant professor, and lead faculty for Health Equity at Rush MD Anderson Cancer Center in Chicago, Illinois.
They discussed the emergence of giredestrant, an investigational oral selective estrogen receptor degrader (SERD), across the hormone receptor–positive, HER2-negative breast cancer treatment paradigm. Unlike aromatase inhibitors, which lower estrogen levels, or tamoxifen, which blocks the estrogen receptor (ER), SERDs degrade the receptor entirely, Dr Nguyen explained. He noted that ESR1 mutations, an acquired resistance mechanism that renders the ER constitutively active, confer worse prognosis and appear to be where oral SERDs derive their strongest signal.
The conversation first addressed the phase 3 evERA Breast Cancer trial (NCT05306340), which randomly assigned patients with previously treated advanced disease to receive giredestrant plus everolimus (Afinitor) or standard-of-care endocrine therapy plus everolimus. Dr Nguyen emphasized the elegance of targeting 2 resistance pathways simultaneously: the endocrine pathway and the parallel mTOR/PI3K/AKT axis. The combination significantly improved median progression-free survival in both the population with ESR1-mutated disease and the intention-to-treat population, though the experts cautioned that the patients with ESR1-mutated disease likely drove the overall benefit, as wild-type outcomes mirrored those in the control arm. The experts characterized giredestrant-associated adverse effects as largely everolimus-driven, most notably stomatitis, and highlighted class-associated bradycardia. They also noted that no photopsia was reported.
They then turned to the phase 3 lidERA Breast Cancer trial (NCT04961996), in which patients with predominantly high-risk, early-stage disease received giredestrant or standard endocrine therapy. Giredestrant produced a reduction in the risk of invasive disease recurrence or death, with markedly lower discontinuation rates and consistent benefit across premenopausal and postmenopausal subgroups.
Finally, the experts contextualized findings from the negative first-line persevERA Breast Cancer trial (NCT04546009), concluding that a single negative readout does not close the oral SERD story, and that thoughtful patient selection will define giredestrant’s future role in the breast cancer treatment armamentarium.

Highlights from the PER® CME activity "Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.
In this podcast, focusing on precision oncology in non-small cell lung cancer (NSCLC), experts Helena Yu, MD; Jacob Sands, MD; and Sarah Goldberg MD, MPH; will discuss the rapidly evolving landscape of Human Epidermal growth factor Receptor 2 (HER2)- and Trophoblast cell-surface antigen 2 (TROP2)-directed therapies in NSCLC. The podcast covers the spectrum of targeted agents from antibody-drug conjugates (ADCs) to novel HER2-selective tyrosine kinase inhibitors (TKIs), along with key clinical trial data and practical strategies for managing the unique adverse event profiles associated with these treatments.
Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/medical-crossfire-precision-oncology-in-nsclc-translating-her2-and-trop2-innovation-into-practice-changing-care-mr5q
This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.
This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

In today’s episode, we welcomed Charles E. Geyer, MD, to discuss recent FDA approvals of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the management of HER2-positive breast cancer. Dr Geyer is a professor of medicine and chief of Malignant Hematology and Medical Oncology in the Department of Medicine at the University of Pittsburgh and the University of Pittsburgh Medical Center Hillman Cancer Center in Pennsylvania.
On May 15, 2026, the FDA approved T-DXd for the neoadjuvant treatment of adult patients with HER2-positive stage II or III breast cancer, as determined by an FDA-authorized test, followed by a taxane, trastuzumab (Herceptin), and pertuzumab (Perjeta); the regulatory agency simultaneously approved post-neoadjuvant T-DXd for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment.
In our exclusive interview, Dr Geyer discussed the significance of these approvals, key data from the pivotal trials, and how these new indications for T-DXd are shaking up the HER2-positive breast cancer treatment paradigm.

In today’s episode, we spoke with Martin Schoen, MD, and Andrew W. Hahn, MD. Dr Schoen is a hematologist/oncologist and hospitalist at St. Louis Veterans Affairs Medical Center and Assistant Professor of Medicine at Saint Louis University. Hahn is an assistant professor in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center.
In our exclusive interview, Drs Schoen and Hahn discussed the clinical evidence for androgen receptor pathway inhibitors (ARPIs), including enzalutamide, in patients with de novo metastatic castration-sensitive prostate cancer (mCSPC) who are elderly, frail, or have a high comorbidity burden. They also highlighted findings from a subgroup analysis the Veterans Affairs dataset evaluating outcomes with androgen deprivation therapy plus ARPIs in high-comorbidity, frail, and elderly patients with high-volume mCSPC.

In today’s episode, we welcomed Claire Harrison, MD, a professor of myeloproliferative neoplasms and clinical director at Guy's and St Thomas' NHS Foundation Trust in London, United Kingdom.
In the exclusive interview, Dr Harrison discussed management strategies for anemia in patients with myelofibrosis and the implications of the phase 3 INDEPENDENCE trial (NCT04717414) presented at the 2026 EHA Congress. Dr Harrison detailed the prevalence and current challenges in managing myelofibrosis-associated anemia. She also detailed key efficacy outcomes reported for luspatercept-aamt (Reblozyl) in the INDEPENCENCE study, along with outlining some of the factors that contributed to the study narrowly missing statistical significance for its primary end point of red blood cell transfusion independence for at least 12 consecutive weeks during the first 24 weeks of treatment.